Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection

Giovanni Guaraldi; Roberto Rossotti; Gabriella Verucchi; Marcello Tavio; Luisa Pasulo; Barbara Beghetto; Giovanni Dolci; Giulia Nardini; Lorenzo Badia; Anna Magliano; Maria Cristina Moioli; Massimo Puoti; HIV/HCV Italian Liver Transplant Group

doi:10.1093/ofid/ofx065

Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection

Open Forum Infect Dis. 2017 May 29;4(2):ofx065. doi: 10.1093/ofid/ofx065. eCollection 2017 Spring.

Collaborators

HIV/HCV Italian Liver Transplant Group:
Giovanna Travi, Annamaria Pazzi, Luciano De Carlis, Alessandro Giacomoni, Andrea Lauterio, Iacopo Mangoni, Stefano Di Sandro, Fabio Ferla, Stefano Fagiuoli, Michele Colledan, Giuliana Cologni, Fabrizio Di Benedetto, Giuseppe Tarantino, Valentina Serra, Giovanni Dolci

Affiliations

¹ Infectious Diseases Departments of University of Modena, Italy.
² ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
³ University of Bologna, Italy.
⁴ Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona, Italy; and.
⁵ Gastroenterology Department ASST Papa Giovanni XXIII, Bergamo, Italy.

Abstract

This retrospective study reports the data of sofosbuvir-based anti-hepatitis C virus treatment in 24 candidates and 24 recipients of liver transplantation coinfected with human immunodeficiency virus. Sustained virologic response was cumulatively 85% (90% and 100% in those treated with optimal schedules pre- and posttransplant, respectively).

Keywords: HCV; HIV; NS5A inhibitors; liver transplantation; sofosbuvir..